Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial

Abstract

We performed a prospective study to investigate the efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone in non-Hodgkin lymphoma patients receiving R-CEOP or CEOP chemotherapy regimen. All patients were randomly assigned to either an aprepitant regimen (aprepitant plus ondansetron and prednisone), or a control regimen (ondansetron and prednisone) treatment group. For the complete response, the aprepitant group was statistically superior to the control group in the overall study period (76.5% vs. 56.0%; p = .03), as well as in separate analyses of the acute phase (92.2% vs. 78.0%; p = .045), and even more notably in the delayed phase (82.4% vs. 64.0%; p = .037). The overall incidence of adverse events was similar between the two treatment groups (p > .05). The aprepitant regimen was more effective than the control regimen for the prevention of CINV in patients receiving R-CEOP or CEOP regimen and was generally well tolerated.

Keywords:

• Aprepitant
• CINV
• CEOP regimen
• non-Hodgkin lymphoma

Acknowledgements

The authors greatly appreciate Merck Sharp & Dohme because of supplying gratuitously all the drugs in this clinic trial.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.1080/10428194.2016.1213838.